N-propionylated polysialic acid (NPPSA)

N-propionylated polysialic acid (NPPSA) is a synthetic carbohydrate antigen designed to overcome immune tolerance to natural polysialic acid (polySia), a glycan typically found on the Neural Cell Adhesion Molecule (NCAM) (Source: Krug et al., Clinical Cancer Research, 2004). PolySia is highly expressed on various neuroendocrine tumors, including small cell lung cancer (SCLC) and neuroblastoma, where it contributes to tumor cell migration and metastasis (Source: Zhang et al., Cancer Research, 2007). Because natural polySia is a self-antigen expressed during embryonic development, the human immune system does not readily mount an attack against it. By substituting the N-acetyl group of sialic acid with an N-propionyl group, NPPSA becomes significantly more immunogenic while maintaining a structure that allows induced antibodies to cross-react with the natural N-acetylated form on tumor surfaces (Source: Hamanaka et al., Cancer Research, 2001). This modification is the basis for investigational cancer vaccines, often conjugated to carrier proteins like Keyhole Limpet Hemocyanin (KLH) to stimulate a robust IgG response and subsequent complement-mediated lysis of tumor cells. While the primary therapeutic goal is the destruction of polySia-positive malignant cells, potential safety concerns include autoimmune cross-reactivity with healthy neural tissues where polySia expression persists in the adult brain (Source: Rutishauser, Nature Reviews Neuroscience, 2008).

Other names

N-propionyl-polysialic acidN-propionylated poly(alpha 2,8-sialic acid)N-propionylated colominic acidNPPSA

Acts as an immunogenic mimic of natural polysialic acid to induce high-titer IgG antibodies that cross-react with N-acetylated polysialic acid on tumor cells, triggering complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).